PolyMedix presents pre-clinical data for antimicrobial compounds

PolyMedix Inc., presented new pre-clinical data for its novel, defensin-mimetic antimicrobial compounds that showed activity against a broad array of pathogens including anthrax.

The presentations were made at two prestigious scientific meetings including the American Society of Microbiology. The compounds also showed activity against oral mucositis, malaria, candida and foodborne pathogens.

“These data continue to support the breadth and potential of our defensin-mimetic antimicrobial compounds in addressing serious infectious diseases that cause severe human and public health issues,” Dr. Richard Scott, vice president of Research at PolyMedix, said. “The importance of our research is reflected in the high degree of attention it receives from the scientific community. We remain committed to continuing research to further advance these programs and expanding their scope.”

Under a grant from the National Institutes of Health, PolyMedix identified several compounds showing cidal activity against Candida albicans and is active against bacterial or fungi without harming human cells. The company also found that 30 of its compounds are broadly active against at least six of the eight foodborne pathogens tested. PolyMedix has identified compounds with activity against animal models of anthrax and oral mucositis.

Dr. Doron Greenbaum, an assistant professor of pharmacology at the University of Pennsylvania, presented in vitro data showing that PolyMedix’s antimicrobial compounds also show promising therapeutic activity against malaria, killing the parasite that causes malaria in red blood cells without damaging uninfected red blood cells.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.